BioMarin’s Q3 growth meets a lower full-year outlook

Transcript intelligence

What changed

Q3 revenue exceeded $1 billion and grew 32% year over year, according to the supplied earnings analysis. BioMarin lowered FY2026 revenue and EPS guidance, citing an approximately $70 million order-timing deferral from one large international customer and Middle East-related disruption. The analysis also describes four new pipeline assets and says Amicus synergies remain ahead of schedule.

Guidance delta

Management lowered full-year 2026 revenue guidance to $3.8–$3.9 billion and lowered EPS guidance. The supplied analysis attributes the change to order timing and Middle East-related headwinds, rather than weaker demand; it does not provide the prior guidance range or revised EPS range.

Key takeaways

• Q3 revenue topped $1 billion, up 32% year over year, led by growth in metabolic conditions and products including Galafold, Pombility/Opfolda and VOXZOGO.
• The lower FY2026 outlook reflects an approximately $70 million order-timing deferral and Middle East-related disruption, according to the supplied analysis.
• The company added BMN-450, BMN-440, BMN-333 and BMN-28 to its pipeline; the analysis highlights BMN-450 and BMN-440 as development opportunities.
• Amicus cost synergies are described as ahead of schedule, with $220 million expected to be fully realized by 2028.
• VOXZOGO’s hypochondroplasia indication remains subject to regulatory review; the supplied analysis gives a May 30, 2027 PDUFA target date.

Management priorities

• Continue commercial expansion of Galafold, Pombility/Opfolda and VOXZOGO, including global diagnosis and newborn-screening initiatives.
• Advance the newly added clinical assets, including BMN-450 and BMN-440, through planned development work.
• Realize the Amicus acquisition’s cost synergies, which the analysis says are ahead of schedule.
• Prepare for a potential VOXZOGO hypochondroplasia launch following the stated regulatory decision date.